|Bid||1,656.00 x 16300|
|Ask||1,608.50 x 34600|
|Day's Range||1,655.50 - 1,709.00|
|52 Week Range||1,204.00 - 2,089.00|
|Beta (3Y Monthly)||0.51|
|PE Ratio (TTM)||14.23|
|Forward Dividend & Yield||0.40 (2.23%)|
|1y Target Est||N/A|
Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices
Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC , today announced the appointment of Kristy Ronco as Executive Vice President, Sales and Marketing for its Generics Division.
Hikma Pharmaceuticals PLC (the Hikma Group) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), the multinational generic pharmaceutical company, announced today that its US business has begun releasing significant quantities of hydromorphone to US hospital customers to help ease a current shortage of injectable opioids used to treat patients. In response to this shortage, Hikma released more than five million hydromorphone 2ml vials to US hospitals during June, and expects to release another three million vials during July. The current US hospital shortage of injectable opioids used for patient pain management occurred when a significant supplier to the US market temporarily ceased manufacturing.